ArticleThe World Allergy Organization journal2025
Response to comments on "Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab".
Koremasa Hayama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.